Notice of Results

Vectura Group plc

Notice of Results

Chippenham, UK - 09 May 2013: Vectura Group plc (LSE: VEC) ("Vectura"), which specialises in developing inhaled therapies, principally for the treatment of respiratory diseases, will be announcing its preliminary results for the year ended 31 March 2013 on Tuesday 21 May 2013. A webcast of the event will be available on the Company's website at www.vectura.com.

Enquiries

About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.